Humana (HUM) to Release Quarterly Earnings on Wednesday

Humana (NYSE:HUM) is scheduled to be releasing its earnings data before the market opens on Wednesday, April 24th. Analysts expect Humana to post earnings of $6.06 per share for the quarter. Individual interested in listening to the company’s earnings conference call can do so using this link.

Humana (NYSE:HUM) last released its quarterly earnings results on Thursday, January 25th. The insurance provider reported ($0.11) EPS for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.87). Humana had a net margin of 2.34% and a return on equity of 19.44%. The company had revenue of $26.46 billion during the quarter, compared to the consensus estimate of $25.47 billion. During the same quarter last year, the firm posted $1.62 EPS. The company’s quarterly revenue was up 17.9% on a year-over-year basis. On average, analysts expect Humana to post $16 EPS for the current fiscal year and $23 EPS for the next fiscal year.

Humana Price Performance

Shares of HUM opened at $325.30 on Tuesday. The business has a 50-day moving average of $330.09 and a 200-day moving average of $399.70. Humana has a 1 year low of $299.23 and a 1 year high of $541.21. The company has a market capitalization of $39.25 billion, a price-to-earnings ratio of 16.41, a price-to-earnings-growth ratio of 1.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.59 and a quick ratio of 1.59.

Humana Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $3.54 annualized dividend and a yield of 1.09%. Humana’s payout ratio is 17.86%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Cantor Fitzgerald reiterated a “neutral” rating and set a $391.00 price objective on shares of Humana in a research report on Wednesday, April 10th. The Goldman Sachs Group cut their price target on shares of Humana from $450.00 to $385.00 and set a “buy” rating on the stock in a research report on Wednesday, April 3rd. Bank of America reissued a “neutral” rating and issued a $342.00 price objective (down from $470.00) on shares of Humana in a research report on Tuesday, April 2nd. Truist Financial reissued a “hold” rating and issued a $550.00 price objective on shares of Humana in a research note on Friday, January 19th. Finally, UBS Group reaffirmed a “neutral” rating and set a $370.00 target price (down previously from $530.00) on shares of Humana in a research note on Friday, January 26th. Eleven investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $454.63.

Insider Buying and Selling at Humana

In other Humana news, Director Jorge S. Mesquita bought 545 shares of the firm’s stock in a transaction dated Tuesday, February 20th. The stock was bought at an average cost of $367.09 per share, with a total value of $200,064.05. Following the completion of the transaction, the director now directly owns 2,578 shares in the company, valued at approximately $946,358.02. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 0.29% of the company’s stock.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.